Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Cancer risk for non-daily smokers 4 times higher than non-smokers
04:58pm, Wednesday, 03'rd Jun 2020
Occasional smokers are nearly four times as likely to die from smoking-related cancers as non-smokers, a study published Wednesday has found. Daily smokers are nearly five times as likely to die, rese
Biomedical Scientists Create a New Tool for Developing COVID-19 Treatments & Vaccines
11:59am, Wednesday, 03'rd Jun 2020
Biomedical scientists working with COVID-19 have an important new tool to help them better understand the virus and feel confident about the structural models they are using in their research. Wladek
Hype Collides With Science As FDA Tries To Rein In ‘Wild West’ of COVID Blood Tests
09:00am, Wednesday, 03'rd Jun 2020
Amid questions about the accuracy of the COVID-19 antibody tests flooding the market — and the usefulness of the results they provide — the FDA has belatedly stepped in to try to rein in the chaos
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering
08:01pm, Tuesday, 02'nd Jun 2020
The shares of common stock issued and sold in the offering include 2,540,322 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public off
Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know
04:00pm, Tuesday, 02'nd Jun 2020
Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Mini Human Livers Grown in Lab Successfully Transplanted Into Rats
03:00pm, Tuesday, 02'nd Jun 2020
Using skin cells from human volunteers, researchers at the University of Pittsburgh School of Medicine have created fully functional mini livers, which they then transplanted into rats. In this proof-
New Evidence Suggests Early Spread is Common in Lung and Breast cancers
01:42am, Tuesday, 02'nd Jun 2020
In the context of improving success in lung and breast cancer management, Stanford research points to the seeds of spread being planted…
Hedge Funds Aren’t Done Buying Iovance Biotherapeutics, Inc. (IOVA)
01:20pm, Monday, 01'st Jun 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
OncoSil Medical (ASX:OSL) Presentation, FNN Online Investor Event, May 2020
10:06pm, Sunday, 31'st May 2020
01 Jun 2020 - OncoSil Medical Limited (ASX:OSL) Managing Director and CEO Daniel Kenny presents on the significance of the company's CE Marking approval for its lead product OncoSil, which helps treat
How You Can be Infected Into Liking Cats
06:51pm, Saturday, 30'th May 2020
A bacteria which overrules rational thought in both humans and rodents
Iovance Biotherapeutics, Inc. (IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today presented long-term interim data from Cohort 2 in the C-144-01 stud
Aurinia Files NDA, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:AUPH)
02:52am, Friday, 29'th May 2020
Aurinia filed an NDA for voclosporin. The FDA accepts a refiled application from Kala Pharma. Syndax reports disappointing results.
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of Approximately $525 Million of Common Stock
01:30am, Friday, 29'th May 2020
In addition, Iovance has granted the underwriters a 30-day option to purchase up to 2,540,322 additional shares of common stock at the public offering price, less the underwriting discounts and commis
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of targeted cancer immunotherapies and vaccines
A Public Offering Undercut This Biotech Stock's Promising Cancer Data
08:35pm, Thursday, 28'th May 2020
Iovance unveiled promising test results for a cancer treatment, but IOVA stock tumbled Thursday on a subsequent public offering. Proceeds will be used, in part, to launch the drug.
